Granahan Investment Management, LLC Immuno Gen, Inc. Transaction History

Granahan Investment Management, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$12.46 - $29.95 $7.01 Million - $16.8 Million	-562,361 Reduced 82.53%	119,016 $3.53 Million
Q3 2023 Nov 14, 2023	BUY	$14.09 - $19.87 $3.59 Million - $5.06 Million	254,625 Added 59.67%	681,377 $10.8 Million
Q2 2023 Aug 14, 2023	SELL	$3.75 - $20.05 $1.64 Million - $8.78 Million	-438,014 Reduced 50.65%	426,752 $8.05 Million
Q1 2023 May 15, 2023	SELL	$3.67 - $4.92 $4.85 Million - $6.5 Million	-1,321,192 Reduced 60.44%	864,766 $3.32 Million
Q4 2022 Feb 14, 2023	BUY	$4.55 - $6.31 $1.41 Million - $1.95 Million	308,998 Added 16.46%	2,185,958 $10.8 Million
Q3 2022 Nov 14, 2022	SELL	$4.48 - $6.47 $21,665 - $31,288	-4,836 Reduced 0.26%	1,876,960 $8.97 Million
Q2 2022 Aug 15, 2022	SELL	$3.15 - $5.76 $239,157 - $437,316	-75,923 Reduced 3.88%	1,881,796 $8.47 Million
Q1 2022 May 16, 2022	BUY	$4.26 - $7.48 $2.94 Million - $5.17 Million	691,029 Added 54.55%	1,957,719 $9.32 Million
Q4 2021 Feb 14, 2022	BUY	$4.75 - $7.5 $2.8 Million - $4.42 Million	589,072 Added 86.93%	1,266,690 $9.4 Million
Q3 2021 Nov 15, 2021	BUY	$5.02 - $6.59 $3.4 Million - $4.47 Million	677,618 New	677,618 $3.84 Million

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Granahan Investment Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Granahan Investment Management, LLC with notifications on news.